Pressure Biosciences (PBIO) Has Growing Revenues and Life Sciences Technology That Could Disrupt How We Alter Molecules
Pressure BioSciences, Inc. (OTCQB: PBIO) engages in the development and sale of pressure-based solutions for the life sciences and other industries.
Current price $2.37/ share
Public float 6.27M shares
PBIO has the pressure based technology to reduce compounds into nan dimensions making them viable for biopharma, agricultural, and industrial applications.
I’ve been watching PBIO for a while and now is the time to talk about the potential for a near term strong swing in valuation. This company has disruptive biotechnology, and their revenues are growing ($1.87M ttm and $608K in Q2 2021). As you begin to familiarize yourself with PBIO you may be surprised that this company is only valued at $15M. Another fact about PBIO that could churn the waters in a potential swing is their tiny share structure, 6.37M share outstanding and 6.27M shares in the float.
When I look at the company stock chart, I see a SMA 20 and SMA 200 both at $2.39 and an SMA 50 at $2.50. This may indicate a potential breakout once the shares reach $2.50. The current RSI (14) is at 46.64. I believe these data could indicate shares that may be on the verge of a breakout.
In early July, PBIO announced it had developed UST technology to convert oil based astaxanthin into a water-soluble compound (more on this below). Astaxanthin can strengthen immune systems, improve muscle endurance, support heart and brain health, protect skin against UV damage, stop premature aging of the skin, and more.
Within days of that announcement the company shares went from $2.45 up to $4.98/share (+ 103%). This indicates to me that a catalyst can drive the company shares to a breakout. Since that event in July, the company shares have consolidated and have been hovering around the current price, indicating a possible support level and the potential for another breakout.
When I look at the recent headlines from articles about PBIO, I can see the potential for a near term catalyst:
Top Astaxanthin Producers Turning to Pressure BioSciences to Increase Quality and Scale Production of World’s Most Potent Antioxidant
Pressure BioSciences Announces Forward Integration Plans for Ultra Shear Technology Demonstration and Toll Manufacturing Partnerships on U.S. West and East Coasts
Pressure BioSciences UST Platform Successfully Transforms Neem Oil into a Novel, Highly Potent Nanoemulsion for More Effective Agrochemical Applications
The technology at PBIO is “outside the box” and disruptive in nature. In the past, molecules have been altered in the lab and throughout industry by applying heat, cold or chemicals to them. Now PBIO can alter molecules by applying pressure, intense pressure like up to 45k psi. PBIO got its first grant from the FDA, $1M by proposing it could make milk that is just the same as the pasteurized milk we drink now but will have a six-month shelf life.
PBIO has developed three patented (currently 29 patents), pressure-enhanced platforms. I’ve included a couple resources below that will detail the technology but here is the condensed version:
The Pressure Cycling Technology (PCT) uses alternating cycles of hydrostatic pressure to control bio-molecular interactions safely and reproducibly, critical steps performed by hundreds of thousands of scientists.
The BaroFold Platform employs high pressure for the disaggregation and controlled refolding of proteins to their native structures at yields and efficiencies not achievable using existing technologies.
The Ultra Shear Technology (UST) Platform is based on the use of ultra-high pressure to turn hydrophobic extracts into stable, water-soluble formulations
I urge you, as part of your due diligence, to look at a couple of resources to further grasp the importance of the PBIO technology. The first would be this video presentation from the Emerging Growth Conference a month ago, featuring PBIO founder and CEO Richard T. Schumacher. You should also visit the company website where they do an excellent job of describing how their technology works and it’s current and potential applications.
While PBIO counts most major pharma companies as partners and customers (the company sells hardware and consulting services) they have caught the attention of the C-B-D sector as well. The PBIO UST technology that I mentioned above that turns oil based astaxanthin into a water-soluble compound easily absorbed in the body can apply to C-B-D oil as well.
Stay tuned for my full report, there is potentially much more to unfold on PBIO.
The Traders News Group
Do we disclose any information to outside parties?
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small acp stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.
Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.